A Phase 3 Extension Study of RAD011 (Cannabidiol Oral Solution) in Patients With Prader-Willi Syndrome

Prader-Willi syndrome

The Intervention of Obesity in Children With Prader-Willi Syndrome Using Prebiotics and Probiotics Biological Age Assessment in Adults With Prader-Willi Syndrome (ETABIOLPWS) Development of a Newborn Screening Assay for Angelman Syndrome and Prader-Willi Syndrome Characterization of Serum Proteome in Subjects With Prader Willi Syndrome (PROTEOMARKER) Guanfacine Extended Release for the Reduction of Aggression and Self-injurious Behavior Associated With Prader-Willi Syndrome Open-Label Extension Study of DCCR in Patients With Prader-Willi Syndrome Understanding the Role of Gut Microbiota in Hyperphagia in Prader-Willi Syndrome A Pharmacokinetic and Safety Study of CSTI-500 in Subjects With Prader-Willi Syndrome A Phase 3 Extension Study of RAD011 (Cannabidiol Oral Solution) in Patients With Prader-Willi Syndrome Study to Evaluate Efficacy, Safety, and Tolerability of RGH-706 in Prader-Willi Syndrome Effect of Intranasal Oxytocin on Dysphagia in Children and Adolescents With Prader-Willi Syndrome Improving Care of Prader-Willi Syndrome : Evaluation of a New Care Program Combining Adapted Physical Activity, Nutrition and Therapeutic Education Study of Tesomet With Open-label Extension in Subjects With Prader-Willi Syndrome A Study of Oral ARD-101 in Patients With Prader-Willi Syndrome A Phase 2/3 Study of RAD011 (Cannabidiol Oral Solution) for the Treatment of Patients With Prader-Willi Syndrome Long-term Interventional Follow-up Study of Children With Prader-Willi Syndrome Included in the OTBB3 Clinical Trial Study of the Efficacy and Safety of Somatropin in Japanese Participants With PWS Assessment of CAI in Adults With PWS. Probiotic Treatment for Prader-Willi Syndrome Prader-Willi Syndrome Body Composition Study of Emotion and Cognition Abilities of Children With PWS and Proposition of an Innovative Remediation Global Growth Hormone Study in Adults With Prader-Willi Syndrome Bioequivalence of Two Somatropin Products (Norditropin® Versus Genotropin®) in Healthy Adult Volunteers GH in Adults With PWS, Effect on Hypotonia Evaluated by Functional MRI, Relationship With Strength and Body Composition Evaluation of Tolerance, Suckling and Food Intake After Repeated Nasals Administrations of Oxytocin in PWS Infants Tolerance of Intranasal Administration of OT in Prader-Willi Newborn Babies Home-based SSP on Individuals With PWS A 5 Treatment Period Pharmacokinetic Study Evaluating Dose Proportionality and Food Effects of Diazoxide Choline Controlled-Release Tablet (DCCR) PREPL in Health and Disease Macronutrient Regulation of Ghrelin and Peptide YY PWS European Blood Bank for Infants and Controls From 0 to 48 Months PWS Outcomes Assessment Study Comparative Study Between Prader-Willi Patients Who Take Oxytocin Versus Placebo Correlation of Hyperghrelinemia With Carotid Artery Intima-Media Thickness in Children With Prader-Willi Syndrome Proof of Concept Study of Vagus Nerve Stimulation Characterization of Transcriptional Regulators of Ghrelin Hormone Which Causes Genetic Obesity Post Exercise Irisin Levels in PWS Patients Oxygen Versus Medical Air for Treatment of CSA in Prader Will Syndrome Exploring Stress and Coping Behaviors of the Major Carer Whose Children With Prader-Willi Syndrome An Efficacy, Safety, and Pharmacokinetics Study of Beloranib in Obese Subjects With Prader-Willi Syndrome Effects of Progressive Elastic Band Resistance Training An Open-Label Study of DCCR Tablet in Patients With PWS Ghrelin Suppression by Octreotide in Prader-Willi Mitochondrial Complex I Dysfunction in PWS Natural History Study of Serious Medical Events in PWS Growth Hormone Use in Adults With Prader-Willi Syndrome The Intestinal Function in People With Prader-Willi Syndrome Study of the Efficacy of Topiramate in Patients With Prader Willi Syndrome Over 8 Weeks A Study to Evaluate the Efficacy and Safety of Recombinant Human Growth Hormone Injection in Patients With Prader-Willi Syndrome Liraglutide Use in Prader-Willi Syndrome Intranasal Oxytocin vs. Placebo for the Treatment of Hyperphagia in Prader-Willi Syndrome CBDV vs Placebo in Children and Adults up to Age 30 With Prader-Willi Syndrome (PWS) Behavioral Treatment of Obsessive-Compulsive Symptoms in Youth With Prader-Willi Syndrome: A Pilot Project Oxytocin vs. Placebo for the Treatment Hyperphagia in Children and Adolescents With Prader-Willi Syndrome Optimizing the Social Engagement System in Prader-Willi Syndrome: Insights From the Polyvagal Theory Fiber Intervention on Gut Microbiota in Children With Prader-Willi Syndrome Nordic Study on the Effects of Growth Hormone (Norditropin SimpleXx) Treatment in Adults With Prader-Willi Syndrome Effect of Rimonabant on Weight Gain and Body Composition in Adults With Prader Willi Syndrome Dose Clinical Trial of Guanfacine Extended Release for the Reduction of Aggression and Self-injuries Behavior Associated With Prader-Willi Syndrome tVNS in Children With Prader-Willi Syndrome Effects of Transcranial Direct Current Stimulation (tDCS) on Individuals With Prader-Willi Syndrome Prader-Willi Syndrome Macronutrient Study Diagnosis of Central Adrenal Insufficiency in Patients With Prader-Willi Syndrome Study to Assess the Efficacy and Safety of Eutropin in Prader-Willi Syndrome Targeting the Gut Microbiome for Prader-Willi Syndrome Treatment Effects of Exenatide on Overweight Adolescents With Prader-Willi Syndrome A Study to Assess the Long-Term Safety of Pharmaceutical Grade Synthetic Cannabidiol Oral Solution in Patients With Prader-Willi Syndrome Effects of Intranasal Administration of Oxytocin in Adults With Prader-Willi Syndrome A Phase 2 Study to Evaluate the Safety and Efficacy of Pitolisant in Patients With Prader-Willi Syndrome, Followed by an Open Label Extension Oxytocin Treatment in Neonates and Infants With Prader-Willi Syndrome Cannabidiol Oral Solution for the Treatment of Subjects With Prader-Willi Syndrome Prader-Willi Syndrome and Appetite Plasma Adiponectin Level and Vascular Endothelial and Smooth Muscle Cell Function in Children With Prader-Willi Syndrome Plasma Adiponectin Level and Sleep Structures in Children With Prader-Willi Syndrome Retrospective Observational Study on Efficacy and Safety of Norditropin® in Children With Prader-Willi Syndrome A Study of GLWL-01 in Patients With Prader-Willi Syndrome Pilot Study of Startle-response Test to Assess Transcranial Direct Current Stimulation-induced Modulation of Hyperphagia in Prader-Willi Syndrome Increased Expression of Adiponectin Receptor 2 in the Mononuclear Cells in Children With Prader-Willi Syndrome Cortisol Activity in Patients With Prader-Willi Syndrome and Healthy Controls Gut Derived Hormones, Body Composition and Metabolism in Prader-Willi Syndrome Register of Patients With Prader-Willi Syndrome Octreotide Therapy in Children and Young Adults With Prader-Willi Syndrome (PWS) Phase 3 Study of Intranasal Carbetocin (LV-101) in Patients With Prader-Willi Syndrome Ph 2 Trial to Evaluate Safety & Efficacy of RM-493 in Obese Patients With Prader-Willi Syndrome Intranasal Oxytocin for Infants With Prader-Willi Syndrome Treatment of Self-Injurious Behavior in Individuals With Prader-Willi Syndrome Effects of Livoletide (AZP-531) on Food-related Behaviors in Patients With Prader-Willi Syndrome Clinical Study of Diazoxide Choline Controlled-Release Tablet (DCCR) in Patients With Prader-Willi Syndrome Stress and Brain Response Using MEG in PWS Therapeutic Effects of Hippotherapy in Children With Prader-Willi Syndrome Double-Blind, Placebo Controlled, Phase 3 Trial of ZGN-440 (Beloranib) in Obese Subjects With Prader-Willi Syndrome Experience With Growth Hormone (GH) in Children Under 2 Years With Prader-Willi Syndrome (PWS) in the Pediatric Endocrine Department of the Hospital of Sabadell Characteristics of Prader-Willi Syndrome and Early-onset Morbid Obesity A Study of Diazoxide Choline in Patients With Prader-Willi Syndrome Open-Label Extension Study of Diazoxide Choline in Patients With Prader-Willi Syndrome Is There a Sensibility Increased in the Growth Hormone at Child With Prader-Willi Syndrome? Oxytocin Intranasal Administrations in Children With Prader-Willi Syndrome Aged From 3 to 12 Years Hypoglycemia in Prader-Willi Syndrome Oxytocin Trial in Prader-Willi Syndrome Deep Brain Stimulation for the Treatment of Obesity in Patients With Prader-Willi Syndrome